Pharmafile Logo
Pharmafocus logo
Advanced Search

Humira

Showing 15 posts of 90 posts found.

Astrazeneca image

RA setbacks for AstraZeneca and Lilly

December 14, 2012
Research and Development, Sales and Marketing AstraZeneca, Humira, RA, lilly

AstraZeneca and Eli Lilly have both suffered setbacks in their attempts to push their respective investigational rheumatoid arthritis (RA) treatments …

News
Humira image

Another indication for Humira

November 28, 2012
Sales and Marketing Abbott, Crohn's, EU, Humira

Abbott’s Humira has received its ninth indication in Europe with approval to treat youngsters suffering from the inflammatory bowel disease …

News
Humira image

Humira continues to drive Abbott

October 22, 2012
Sales and Marketing AbVie, Abbott, Humira, RA

Abbott Laboratories’ rheumatoid arthritis drug Humira has once again shown its value to the company with a strong performance in …

News
Humira image

Humira powers ahead as Abbott prepares split

July 19, 2012
Sales and Marketing AbbVie, Abbott, Humira, RA

Humira maintained its rapid growth in the second quarter, helping keep Abbott buoyant ahead of its split into two separate …

News
AstraZeneca image

AstraZeneca buys Ardea Biosciences

June 22, 2012
Research and Development, Sales and Marketing Abbott, Ardea Biosciences, AstraZeneca, Bayer, Humira, Takeda

AstraZeneca has completed its acquisition of US firm Ardea Biosciences in a $1.26 billion deal that it hopes will shore …

News
RoActemra image

RoActemra superior to Humira as single-agent therapy

June 7, 2012
Research and Development, Sales and Marketing Humira, Orencia, RA, RoActemra, Roche. ADACTA

Roche’s RoActemra (tocilizumab) is more effective in treating rheumatoid arthritis as a single agent than market leader Humira, a new …

News

Pfizer’s RA drug on course for approval

May 10, 2012
Sales and Marketing Humira, JAK inhibitor, Pfizer, RA, rheumatoid arthritis, tofacitinib

An FDA advisory committee has recommended for approval Pfizer’s new rheumatoid arthritis treatment tofacitinib.The Arthritis Advisory Committee voted 8-2 to …

News

Humira gains European licence for ulcerative colitis

April 11, 2012
Sales and Marketing Humira, ulcerative colitis

Abbott’s Humira has gained European approval to treat ulcerative colitis, adding to its six existing licences.   It can now …

News
RoActemra image

Roche’s RoActemra beats Humira in arthritis study

March 5, 2012
Research and Development, Sales and Marketing Humira, RA, RoActemra, Roche, arthritis

Roche’s rheumatoid arthritis drug RoActemra has beaten Abbott’s Humira in a head-to-head study. The Phase IV trial showed that RoActemra …

News
Abbott image

Abbott buys into Galapagos’ RA candidate

February 29, 2012
Research and Development, Sales and Marketing Abbott, Galapagos, Humira, JAK, RA, TNF

Abbott has struck a deal with Galapagos to develop and commercialise a promising oral JAK1 inhibitor to treat multiple autoimmune …

News
Abbott image

Abbott strong as it prepares for spin-out

January 26, 2012
Sales and Marketing Abbott, GAAP, Humira

Abbott enjoyed a strong 2011 thanks to Humira and emerging market growth, with overall worldwide sales rising by 4.1 per …

News

Abbott spin-off could attract mega merger

October 21, 2011
Research and Development, Sales and Marketing Abbott, Bayer, Humira, Merck, Roche

Abbott’s new spin-off pharma firm could attract a lot of attention from big pharma looking to sure up their portfolios. …

News

NICE re-thinks arthritis guidance

June 25, 2010
Sales and Marketing Enbrel, Humira, MabThera, NICE, Orencia, Remicade, TNF, rheumatoid arthritis

NICE has approved five rheumatoid arthritis treatments in certain circumstances after treatment with a tumour necrosis factor inhibitor has failed. …

News

Pfizer still at number 1, but Lipitor to slip

May 4, 2010
Sales and Marketing Humira, Lipitor, Pfizer, sales

New research suggests that the pharma world is going to be shaken up over the next few years – although …

News

Ulcerative colitis market set to double by 2018

February 12, 2010
Sales and Marketing Humira, Simponi, TNF, ulcerative colitis

The market for ulcerative colitis drugs is set to double over the ten years to 2018 when it will hit …

News

Latest content

GSK pledges £45m to Fleming Initiative to fight AMR

May 16, 2024

NeuroSense partners with PhaseV on upcoming phase 3 ALS trial

May 16, 2024

AstraZeneca adds new heart failure target through collaboration with BenevolentAI

May 15, 2024

FDA approves Roche’s HPV self-collection screening option

May 15, 2024

NHS accepts Pfizer’s tafamidis for ATTR-CM treatment

May 14, 2024